The transgenic rabbit as model for human diseases and as a source of biologically active recombinant proteins

被引：54

作者：

Bosze, Z ^{[1
]}

Hiripi, L

Carnwath, JW

Niemann, H

机构：

[1] Agr Biotechnol Ctr, Dept Anim Biol, H-2101 Godollo, Hungary

[2] FAL, Dept Biotechnol, Inst Anim Sci, Neustadt, Germany

来源：

TRANSGENIC RESEARCH | 2003年 / 12卷 / 05期

关键词：

antiviral; bioreactor; cardiomyopathy; lipid metabolism; pharmaceutical; rabbit;

D O I：

10.1023/A:1025816809372

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Until recently, transgenic rabbits were produced exclusively by pronuclear microinjection which results in additive random insertional transgenesis; however, progress in somatic cell cloning based on nuclear transfer will soon make it possible to produce rabbits with modifications to specific genes by the combination of homologous recombination and subsequent prescreening of nuclear donor cells. Transgenic rabbits have been found to be excellent animal models for inherited and acquired human diseases including hypertrophic cardiomyopathy, perturbed lipoprotein metabolism and atherosclerosis. Transgenic rabbits have also proved to be suitable bioreactors for the production of recombinant protein both on an experimental and a commercial scale. This review summarizes recent research based on the transgenic rabbit model.

引用

页码：541 / 553

页数：13

共 126 条

[1] Expression of the murine wild-type tyrosinase gene in transgenic rabbits [J].

Aigner, B ;

Besenfelder, U ;

Seregi, J ;

Frenyo, LV ;

SahinToth, T ;

Brem, G .

TRANSGENIC RESEARCH, 1996, 5 (06) :405-411

[2] Species-specific alternative splicing of transgenic RNA in the mammary glands of pigs, rabbits, and mice [J].

Aigner, B ;

Pambalk, K ;

Reichart, U ;

Besenfelder, U ;

Bosze, Z ;

Renner, M ;

Günzburg, WH ;

Wolf, E ;

Müller, M ;

Brem, G .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (03) :843-850

[3] Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II:: Results of a phase I/II clinical trial [J].

Amalfitano, A ;

Bengur, AR ;

Morse, RP ;

Majure, JM ;

Case, LE ;

Veerling, DL ;

Mackey, J ;

Kishnani, P ;

Smith, W ;

McVie-Wylie, A ;

Sullivan, JA ;

Hoganson, GE ;

Phillips, JA ;

Schaefer, GB ;

Charrow, J ;

Ware, RE ;

Bossen, EH ;

Chen, YT .

GENETICS IN MEDICINE, 2001, 3 (02) :132-138

[4] Reduced expression and increased CpG dinucleotide methylation of the rat APOBEC-1 promoter in transgenic rabbits [J].

Apostel, F ;

Dammann, R ;

Pfeifer, GP ;

Greeve, J .

BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2002, 1577 (03) :384-394

[5] Transgenic rabbits expressing human lipoprotein lipase [J].

Araki, M ;

Fan, JL ;

Challah, M ;

Bensadoun, A ;

Yamada, N ;

Honda, K ;

Watanabe, T .

CYTOTECHNOLOGY, 2000, 33 (1-3) :93-99

[6] NEW DATA ON THE PROTEINS OF RABBIT (ORYCTOLAGUS-CUNICULUS) MILK [J].

BARANYI, M ;

BRIGNON, G ;

ANGLADE, P ;

RIBADEAUDUMAS, B .

COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 1995, 111 (03) :407-415

[7] Overexpression of human hepatic lipase and ApoE in transgenic rabbits attenuates response to dietary cholesterol and alters lipoprotein subclass distributions [J].

Barbagallo, CM ;

Fan, JL ;

Blanche, PJ ;

Rizzo, M ;

Taylor, JM ;

Krauss, RM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :625-632

[8]

BESENFELDER U, 1998, MICROINJECTION TRANS, P561

[9]

Boulanger L., 2002, Transgenic Research, V11, P88

[10] Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-1 with severe hypercholesterolaemia [J].

Boullier, A ;

Hennuyer, N ;

Tailleux, A ;

Furman, C ;

Duverger, N ;

Caillaud, JM ;

Castro, G ;

Fievet, C ;

Fruchart, JC ;

Duriez, P .

CLINICAL SCIENCE, 2001, 100 (03) :343-355

← 1 2 3 4 5 6 7 8 9 10 →